Cancer Treatment Centers of America in Philadelphia Purchases BSD-2000 Hyperthermia System from BSD Medical

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that the Cancer Treatment Centers of America (CTCA) hospital at Eastern Regional Medical Center, located in Philadelphia, Pennsylvania, has purchased a BSD-2000 Hyperthermia System (BSD-2000). CTCA in Philadelphia is a state-of-the-art hospital that provides advanced cancer treatments, world-class technologies, and supportive therapies under one roof. CTCA in Philadelphia provides the most advanced therapeutic resources in cancer treatment ( CTCA is a network of hospitals and one of the premier providers of cancer care in the world. Like all CTCA cancer hospitals, the Philadelphia facility provides an unsurpassed environment of healing and hope. The CTCA hospitals were recently recognized by the Commission on Cancer of the American College of Surgeons as “offering the very best in cancer care.” This will be the fifth BSD Hyperthermia system purchased by CTCA, including three systems purchased within the last five months.

“After successfully performing superficial hyperthermia treatments with the BSD-500 Hyperthermia System at CTCA, we are looking forward to introducing the BSD-2000, with the capacity to treat deep into tissues, to offer our patients even more options to treat their cancer,” said Curt Heese, MD, Radiation Oncologist at CTCA in Philadelphia.

CTCA physicians specialize in treating many types of cancer, including complex and advanced stage cases. The cancer experts employed by CTCA work as a team across multiple disciplines to provide an individualized cancer treatment plan designed to treat the whole person. CTCA is committed to revolutionizing cancer care by providing the most advanced and effective cancer treatments and supportive therapies available in order to treat the cancer and improve the patient’s treatment experience and quality of life.

The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the 3-dimensional shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 is restricted to investigational use in the US, and the Company is currently conducting a clinical study to evaluate the safety and efficacy of hyperthermia using the BSD-2000 combined with radiotherapy for the treatment of patients suffering from locally advanced, persistent, or recurrent deep tumors of the pelvis; i.e., cervical, prostate, rectal, and bladder. BSD has also applied for a Humanitarian Device Exemption (HDE) approval for its BSD-2000 Hyperthermia System and this submission is still under review by the FDA.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information, visit BSD Medical’s website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.


BSD Medical Corporation
Dennis Gauger, 801-972-5555
[email protected]
Fax: 801-972-5930

KEYWORDS:   United States  North America  Pennsylvania  Utah

INDUSTRY KEYWORDS:   Health  Biotechnology  Hospitals  Oncology  FDA